Market capitalization | KRW7.81t |
Enterprise Value | KRW7.70t |
P/E (TTM) P/E ratio | 32.43 |
EV/FCF (TTM) EV/FCF | 84.15 |
EV/Sales (TTM) EV/Sales | 14.05 |
P/S ratio (TTM) P/S ratio | 14.26 |
P/B ratio (TTM) P/B ratio | 14.29 |
Revenue growth (TTM) Revenue growth | 54.30% |
Revenue (TTM) Revenue | KRW547.60b |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
15 Analysts have issued a SK Biopharmaceuticals forecast:
15 Analysts have issued a SK Biopharmaceuticals forecast:
Dec '24 |
+/-
%
|
||
Revenue | 547,596 547,596 |
54%
54%
|
|
Gross Profit | 491,734 491,734 |
59%
59%
|
|
EBITDA | 113,726 113,726 |
603%
603%
|
EBIT (Operating Income) EBIT | 96,299 96,299 |
354%
354%
|
Net Profit | 240,738 240,738 |
832%
832%
|
In millions KRW.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.
Head office | South Korea |
CEO | Dong-Hoon Lee |
Founded | 1993 |
Website | www.skbp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.